Hints and tips:
Related Topics
...Heather Bresch will retire after eight years as Mylan chief executive when the transaction closes....
...The plans would also see Mylan’s chief executive Heather Bresch depart, after leading the company for seven years....
...Heather Bresch, Mylan chief executive, said Mylan’s generic version of Copaxone, a treatment for multiple sclerosis, had a lower than expected uptake, and the company did not receive its approval for a generic...
...Investors welcomed the combination as well as the departure of chief executive Heather Bresch (pictured below)....
...His daughter, Heather Bresch, is chief executive of Mylan, the pharmaceutical company which attained notoriety in 2016 for having raised the price of EpiPen, the adrenaline auto-injector used to treat anaphylactic...
...Heather Bresch, the company’s chief executive, said the results were “directly correlated with the ongoing rebasing of the US healthcare environment”, but that the “fundamentals of Mylan’s global business...
...But a campaign by some investors to oust Mr Coury and Heather Bresch, Mylan’s chief executive, was unsuccessful, while the “say on pay” vote was merely advisory, meaning Mylan does not have to heed it....
...Bresch....
...“Our North America segment was down considerably year-over-year due to delayed launches and the EpiPen,” said Heather Bresch, chief executive. “We expect these dynamics to continue for some time.”...
...raising the price of its EpiPen allergy injection by almost 5,000 per cent since 2007 so its executives could get “filthy rich” at the expense of American taxpayers during a testy congressional grilling of Heather...
...CEO Heather Bresch said: We understand the deep frustration and concerns associated with the cost of EpiPen to the patient, and have always shared the public’s desire to ensure that this important product...
...Last week, Heather Bresch, chief executive of Mylan, told investors that annual price decreases in the “high-single digits [are] probably here for the foreseeable future”....
...Mylan chief executive, Heather Bresch, said: We have been a long-term, committed partner to the allergy community and are taking immediate action to help ensure that everyone who needs an EpiPen Auto-Injector...
...Like the story of Jackson, this particular saga involves an absent degree, however the circumstances could hardly be more different in the case of Heather Bresch, chief executive of Mylan, the US company...
...Heather Bresch, the chief executive, has claimed Mylan deserves a return on its investment in EpiPens. “What investment?” the critics ask....
...A group of influential senators also said they had written to the company’s chief executive, Heather Bresch, demanding that she brief them on the reasons behind the “drastic price increases” within two weeks...
...The company’s CEO, Heather Bresch, has faced intense scrutiny from lawmakers over price increases for EpiPen, which treats severe reactions to allergies....
...Bresch, Mylan chief executive....
...But chief executive Heather Bresch, a skilled lobbyist and the daughter of a Clinton-supporting senator, insisted other companies in the healthcare system were also to blame....
...This week it was the turn of Mylan chief executive, Heather Bresch, who was grilled for more than six hours on Wednesday over her implementation of a string of sharp price increases that took the company...
...Heather Bresch was made chief executive of US-based pharmaceuticals company Mylan in 2012....
...In an unusual twist, the father of Mylan’s chief executive, Heather Bresch, is Joe Manchin, a Democratic senator for West Virginia who is supporting Mrs Clinton’s presidential bid....
...Heather Bresch, Mylan’s chief executive, is due to be grilled on the price increases by US policymakers at a congressional hearing on Wednesday....
...Heather Bresch, Mylan’s chief executive, dismissed concerns that it had paid too much. “It will take a little time for everyone to catch up with the opportunity,” she said....
...“When it comes to opioids, I don’t sit here and wear a hat and say ‘I’m going to hurt my revenue’,” says Heather Bresch, chief executive of Mylan, which makes generic versions of off-patent opioids....
International Edition